Citations 0
Invited Commentary
March 1998

Middle Segment Pancreatectomy—Invited Commentary

Author Affiliations

Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998

Arch Surg. 1998;133(3):331. doi:10.1001/archsurg.133.3.331

The perioperative results with pancreatic resection have improved dramatically during the last decade. At high-volume centers, perioperative mortality has been consistently reported to be less than 5% following pancreaticoduodenectomy. Similarly, distal pancreatectomy can be accomplished with minimal morbidity and rare mortality. Despite these improved results, a few problems remain. One such problem is that cysts and tumors arising in the midbody of the pancreas may not be optimally managed by either distal pancreatectomy or pancreaticoduodenectomy. In many cases the central location of these tumors, which are most often benign if truly candidates for resection, requires a significant extension of the resection either proximally toward the head or distally to include the tail-sacrificing normal pancreatic tissue. These extensive resections frequently result in either pancreatic exocrine or endocrine insufficiency, and with distal pancreatectomy often necessitate splenectomy.

First Page Preview View Large
First page PDF preview
First page PDF preview